Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mesenchymal stem cell therapy - Stemedica Cell Technologies

X
Drug Profile

Mesenchymal stem cell therapy - Stemedica Cell Technologies

Alternative Names: Acute myocardial infarction stem cell therapy - CardioCell; Allogeneic mesenchymal bone marrow cell therapy - Stemedica; Allogeneic mesenchymal bone marrow cells; hMSC - Stemedica Cell Technologies; Ischaemia-tolerant mesenchymal stem cell; itMSC; Marrow stromal cells - Stemedica Cell Technologies; Stemedyne™ MSC; Stroke stem cell therapy - Stemedica Cell Technologies

Latest Information Update: 24 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stemedica Cell Technologies
  • Developer CardioCell; Pulthera; S.N. Fyodorov Eye Microsurgery Complex; StemCutis; Stemedica Cell Technologies
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - SARS-CoV-2 acute respiratory disease

Highest Development Phases

  • Phase II Chronic heart failure; Dementia; SARS-CoV-2 acute respiratory disease; Stroke
  • Phase I/II Skin aging
  • Preclinical Lung disorders
  • No development reported Diabetic retinopathy; Myocardial infarction

Most Recent Events

  • 19 Jan 2023 US FDA approves IND application for allogeneic mesenchymal stem cells in Ischemic stroke before January 2023
  • 19 Jan 2023 Stemedica plans a phase IIb/III trial for Ischemic stroke in USA (IV)
  • 28 Jun 2021 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top